Progenics Pharmaceuticals to Present at the 17th Annual Needham Healthcare Conference

NEW YORK, March 20, 2018 (GLOBE NEWSWIRE) -- Progenics Pharmaceuticals, Inc. (Nasdaq:PGNX), an oncology company developing innovative medicines and imaging analysis technology for targeting and treating cancer, announced today that Mark R. Baker, Chief Executive Officer, will present at the 17th Annual Needham Healthcare Conference in New York City on Tuesday, March 27, 2018 at 3:00 p.m. Eastern Daylight Time.

A live webcast of the presentation will be available in the Media Center of the Progenics website, To ensure a timely connection, users should register at least 15 minutes prior to the scheduled start. An archive of the event will be available for 90 days.

About Progenics

Progenics develops innovative medicines and other technologies to target and treat cancer. Progenics' pipeline includes: 1) therapeutic agents designed to precisely target cancer (AZEDRA®, 1095, and PSMA TTC), 2) PSMA-targeted imaging agents for prostate cancer (1404 and PyL™), and 3) imaging analysis technology. Progenics' first commercial product, RELISTOR® (methylnaltrexone bromide) for opioid-induced constipation, is partnered with Valeant Pharmaceuticals International, Inc.

This press release may contain projections and other "forward-looking statements" regarding future events. Statements contained in this communication that refer to Progenics' estimated or anticipated future results or other non-historical facts are forward-looking statements that reflect Progenics' current perspective of existing trends and information as of the date of this communication. Forward looking statements generally will be accompanied by words such as "anticipate," "believe," "plan," "could," "should," "estimate," "expect," "forecast," "outlook," "guidance," "intend," "may," "might," "will," "possible," "potential," "predict," "project," or other similar words, phrases or expressions. Such statements are predictions only, and are subject to risks and uncertainties that could cause actual events or results to differ materially. These risks and uncertainties include, among others, the cost, timing and unpredictability of results of clinical trials and other development activities and collaborations, such as the Phase 3 clinical program for 1404; our ability to successfully develop and commercialize the products of EXINI Diagnostics AB; the unpredictability of the duration and results of regulatory review of New Drug Applications (NDA) and Investigational NDAs, including our NDA for AZEDRA and related inspections of Progenics’ and its contract manufacturing organizations’ facilities and other sites and other requirements that will need to be met before any approval is obtained; market acceptance for approved products; the effectiveness of the efforts of our partners to market and sell products on which we collaborate and the royalty revenue generated thereby; generic and other competition; the possible impairment of, inability to obtain and costs of obtaining intellectual property rights; possible product safety or efficacy concerns, general business, financial, regulatory and accounting matters, litigation and other risks. More information concerning Progenics and such risks and uncertainties is available on its website, and in its press releases and reports it files with the U.S. Securities and Exchange Commission, including those risk factors included in its Annual Report on Form 10-K for the annual period ended December 31, 2017. Progenics is providing the information in this press release as of its date and, except as expressly required by law, Progenics disclaims any intent or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or circumstances or otherwise.

Additional information concerning Progenics and its business may be available in press releases or other public announcements and public filings made after this release. For more information, please visit Information on or accessed through our website or social media sites is not included in the company's SEC filings.


Contact:       Melissa Downs
 Investor Relations
 (646) 975-2533


You May Also Like


胸部恶性肿瘤界的全球领袖开展调查,以评估如何改善全球分子诊断丹佛, July 13, 2018 (GLOBE NEWSWIRE) -- 国际肺癌研究协会(IASLC)鼓励所有参与肺癌患者分子诊断的人员参加一项全球调查,本调查旨在评估最佳实务的实施情况及最终制定分子诊断的全球指南。欲参加IASLC肺癌分子诊断全球调查,请访问。 IASLC的医学博士、哲学博士和首席执行官Fred R. Hirsch表示,“肺癌科学的发展速度非常快。”Hirsch博士也指出,“为了确保患者护理跟上科学的发展,我们需要了解实施及采用新疗法的障碍。在收集、利用和传播数据以改变患者治疗效果方面,IASLC拥有独特的优势。” 许多指南建议在拥有腺癌组织学成分的晚期非小细胞肺癌(NSCLC)中测试致瘤分子驱动因子,例如EGFR、ROS1、ALK和BRAF。针对这些特定致癌分子驱动因子的疗法可以使患者延年益寿,但是在开始治疗之前需要知道是否存在驱动因子。 为了解肺癌分子诊断的现状以及任何区域性挑战和实施障碍,包括为什么并非所有地区均参与分子诊断,专家参与本调查至关重要。IASLC邀请医疗保健专业人员和其他利益相关方参与本调查。本调查提供英语、中文、日语、葡萄牙语和西班牙语版本。 肺癌分子诊断的IASLC全球调查结果将1)确定分子诊断的现状,2)揭露任何区域实施挑战或障碍,及3)为制定未来策略提供相关信息,以克服向全球肺癌患者普及分子诊断的障碍。主要发现摘要将与受访者分享,并且完整报告将会提交至IASLC官方期刊Journal ...